MUSTANG BIO, INC. Proceeds from Lines of Credit
MUSTANG BIO, INC. (MBIO) reported Proceeds from Lines of Credit of $15.00 million for the 1-month period ending 2019-03-29, per its 10-Q filed 2019-05-10.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromLinesOfCredit · last filed 2019-08-09
- 2019-03-29: Proceeds from Lines of Credit 1 month $15.00M.
| Period end | Proceeds from Lines of Credit 1 month |
|---|---|
| 2019-03-29 | $15.00M 10-Q · filed 2019-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B |